Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Biodesix Inc (BDSX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: BDSX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $1.8
1 Year Target Price $1.8
| 4 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -53.27% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 39.81M USD | Price to earnings Ratio - | 1Y Target Price 1.8 |
Price to earnings Ratio - | 1Y Target Price 1.8 | ||
Volume (30-day avg) 6 | Beta 0.98 | 52 Weeks Range 0.17 - 2.04 | Updated Date 07/4/2025 |
52 Weeks Range 0.17 - 2.04 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -54.28% | Operating Margin (TTM) -50.47% |
Management Effectiveness
Return on Assets (TTM) -23.33% | Return on Equity (TTM) -1454.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 84488519 | Price to Sales(TTM) 0.53 |
Enterprise Value 84488519 | Price to Sales(TTM) 0.53 | ||
Enterprise Value to Revenue 1.13 | Enterprise Value to EBITDA -2.72 | Shares Outstanding 146563008 | Shares Floating 62032803 |
Shares Outstanding 146563008 | Shares Floating 62032803 | ||
Percent Insiders 52.11 | Percent Institutions 36.46 |
Upturn AI SWOT
Biodesix Inc
Company Overview
History and Background
Biodesix, Inc. was founded in 2005 and is headquartered in Boulder, Colorado. It focuses on developing and commercializing diagnostic tests for lung cancer and other pulmonary diseases.
Core Business Areas
- Lung Diagnostic Tests: Develops and sells blood-based diagnostic tests to improve treatment decisions and outcomes for lung cancer patients. Offerings include Nodify Lung, GeneStrat, and VeriStrat.
- Pulmonary Disease Testing: Offers tests for other pulmonary diseases beyond lung cancer, aimed at improving diagnosis and management.
- Biomarker Discovery: Conducts research and development activities to discover and validate new biomarkers for disease detection.
Leadership and Structure
The leadership team includes Scott Hutton (CEO). The organizational structure consists of research, development, commercial, and administrative departments.
Top Products and Market Share
Key Offerings
- Nodify Lung Nodule Risk Assessment: A blood-based test to assess the risk of malignancy in lung nodules. Competitors: Veracyte (VCYT) with Percepta Nasal Swab, and other imaging techniques. Market share data is difficult to obtain directly due to competition with imaging techniques and other diagnostic approaches.
- GeneStrat DDx Alteration Identification: A blood-based test for genomic profiling of advanced lung cancer. Competitors: Guardant Health (GH), Foundation Medicine (owned by Roche). Market share data is difficult to obtain directly due to competition with imaging techniques and other diagnostic approaches.
- VeriStrat Proteomic Profiling: A blood-based test used to stratify patients and predict response to EGFR inhibitors and other treatments for lung cancer. Competitors: Thermo Fisher Scientific (TMO) with Oncomine assays, and other proteomic profiling methods. Market share data is difficult to obtain directly due to competition with imaging techniques and other diagnostic approaches.
Market Dynamics
Industry Overview
The diagnostic testing market is growing, driven by increasing cancer incidence and technological advancements. The lung cancer diagnostics segment is highly competitive, with many companies developing and commercializing new tests.
Positioning
Biodesix is positioned as a provider of non-invasive blood-based diagnostic tests for lung cancer. Its competitive advantage lies in its proprietary technologies and expertise in biomarker discovery.
Total Addressable Market (TAM)
The total addressable market for lung cancer diagnostics is estimated to be in the billions of dollars. Biodesix is positioned to capture a significant share of this market through its innovative product offerings.
Upturn SWOT Analysis
Strengths
- Proprietary technologies
- Expertise in biomarker discovery
- Blood-based diagnostic tests offer a non-invasive approach
- Established commercial infrastructure
Weaknesses
- Limited market share compared to larger competitors
- Reliance on a few key products
- Cash burn rate is concerning
Opportunities
- Expanding product portfolio to include other pulmonary diseases
- Partnering with pharmaceutical companies to develop companion diagnostics
- Increasing adoption of blood-based diagnostics in clinical practice
- Geographic expansion
Threats
- Competition from larger diagnostic companies
- Regulatory changes
- Reimbursement challenges
- Technological advancements may render existing tests obsolete
Competitors and Market Share
Key Competitors
- VCYT
- GH
- TMO
Competitive Landscape
Biodesix faces competition from larger diagnostic companies with more resources. Its advantage lies in its specialized focus on lung cancer diagnostics.
Growth Trajectory and Initiatives
Historical Growth: Biodesix's growth has been driven by the adoption of its lung cancer diagnostic tests. Growth rates should be checked against financial reports.
Future Projections: Future growth projections depend on market adoption of new products and expansion into new markets. - Data would require a live source.
Recent Initiatives: Recent initiatives may include new product launches, partnerships, and acquisitions. - Data would require a live source.
Summary
Biodesix is a focused lung cancer diagnostics company with proprietary technologies. It faces strong competition from larger players, but has opportunities for growth through product expansion and partnerships. Its financial performance and cash burn require monitoring. Successful execution of its growth strategy is critical for long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Market share data are estimates and may not be precise. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biodesix Inc
Exchange NASDAQ | Headquaters Louisville, CO, United States | ||
IPO Launch date 2020-10-28 | President, CEO & Director Mr. Scott Hutton | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 273 | Website https://www.biodesix.com |
Full time employees 273 | Website https://www.biodesix.com | ||
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.